RPB5‐mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

RPB5‐mediating protein promotes cholangiocarcinoma tumorigenesis and drug resistance by competing with NRF2 for KEAP1 binding
Hepatology ( IF 12.9 ) Pub Date : 2020-02-20 , DOI: 10.1002/hep.30962
Zheng-Hua Wan _{1,

2} , Tian-Yi Jiang _{1,

3} , Yuan-Yuan Shi ₁ , Yu-Fei Pan ₃ , Yun-Kai Lin _{1,

3} , Yun-Han Ma _{1,

3} , Chun Yang _{3,

4} , Xiao-Fan Feng ₁ , Li-Feng Huang ₅ , Xiao-Ni Kong ₅ , Zhi-Wen Ding ₁ , Ye-Xiong Tan ₃ , Li-Wei Dong ₁ , Hong-Yang Wang _{1,

3,

6,

7}

Affiliation

Cancer cell survival depends on the balance between reactive oxygen species production and scavenging, which is regulated primarily by NRF2 during tumorigenesis. Here, we demonstrate that deletion of RBP5‐mediating protein (RMP) in an autonomous mouse model of intrahepatic cholangiocarcinoma (ICC) delays tumor progression.

中文翻译：